Instem plc Notice of Results (8757T)
March 30 2021 - 1:00AM
UK Regulatory
TIDMINS
RNS Number : 8757T
Instem plc
30 March 2021
Instem plc
("Instem" or the "Company")
Notice of Results
Instem plc (AIM: INS), a leading provider of IT solutions to the
global life sciences market, will announce results for the year
ended 31 December 2020 on Monday 12 April 2021.
Analyst Presentation: 11:00, Monday 12 April
Management will be hosting a presentation via web conference on
the day of the results at 11:00. Analysts wishing to join should
register their interest by emailing instem@walbrookpr.com or by
telephoning 020 7933 8780.
Investor Presentation: 16:00, Monday 12 April
Management will be providing a presentation and hosting an
Investor Q&A session on the results and future prospects at
16:00hrs on the day, through the digital platform Investor Meet
Company. Investors can sign up for free and add to attend the
presentation via the following link
https://www.investormeetcompany.com/instem-plc/register-investor
Questions can be submitted pre-event via your Investor Meet
Company dashboard up until 9am the day before the meeting or at any
time during the live presentation.
For further information, please contact:
Instem plc Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser
& Broker) +44 (0) 20 7496 3000
Peter Steel
Alex Bond
Rachel Hayes
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
Nicholas Johnson
About Instem
Instem is a leading provider of IT solutions & services to
the life sciences market delivering compelling solutions for Study
Management and Data Collection; Regulatory Solutions for
Submissions and Compliance; and Informatics-based Insight
Generation.
Instem solutions are in use by over 500 customers worldwide,
including all the largest 25 pharmaceutical companies, enabling
clients to bring life enhancing products to market faster. Instem's
portfolio of software solutions increases client productivity by
automating study-related processes while offering the unique
ability to generate new knowledge through the extraction and
harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug
development value chain, from discovery through to market launch.
Management estimate that over 50% of all drugs on the market have
been through some part of Instem's platform at some stage of their
development.
To learn more about Instem solutions and its mission, please
visit www.instem.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORFZGZFRLRGMZM
(END) Dow Jones Newswires
March 30, 2021 02:00 ET (06:00 GMT)
Instem (LSE:INS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Instem (LSE:INS)
Historical Stock Chart
From Apr 2023 to Apr 2024